Given the disparity in the numbers of cerebrovascular and cardiovascularclinical trials and the similarities in the interventions tested,it seems that stroke neurologists have had to peer at clinical-trialresults over the shoulders of their cardiologist colleaguesso often that they are at risk for chronic neck ailments. Ifonly for evening the score a little, the Stroke Prevention byAggressive Reduction in Cholesterol Levels (SPARCL) investigatorsdeserve our gratitude.
In their randomized clinical trial that was specifically designedto test statin therapy for the prevention of stroke recurrencein patients who had had a stroke or transient ischemic . . . [Full Text of this Article]
Source Information
From the Institute for Clinical Research and Health Policy Studies, TuftsNew England Medical Center, Boston.
Henyan, N. N, Riche, D. M, East, H. E, Gann, P. N
(2007). Impact of Statins on Risk of Stroke: A Meta-Analysis. The Annals of Pharmacotherapy
41: 1937-1945
[Abstract][Full Text]
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., Moher, D.
(2007). How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis. ANN INTERN MED
147: 224-233
[Abstract][Full Text]
Cohen, J. S., East, J. E., Elkind, M. S.V., Khan, N. A., Mascitelli, L., Pezzetta, F., Welch, K.M.A., the SPARCL Investigators, , Kent, D.
(2006). Statin Therapy after Stroke or Transient Ischemic Attack. NEJM
355: 2368-2371
[Full Text]